| Entry |
|
|---|
| Name |
Pidilizumab (USAN/INN) |
|---|
| Formula |
C6424H9920N1704O2002S48
|
|---|
| Exact mass |
144503.3409
|
|---|
| Mol weight |
144592.93
|
|---|
| Class |
Antineoplastic
DG02938 Immune checkpoint inhibitor
|
|---|
| Efficacy |
Antineoplastic, Anti-PD-1 antibody |
|---|
| Type |
Monoclonal antibody |
|---|
| Comment |
Treatment of cancer and infectious diseases
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04514 | Cell adhesion molecule (CAM) interaction |
| hsa04660 | T cell receptor signaling pathway |
| hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer |
|
|---|
| Brite |
Drug groups [BR:br08330]
Antineoplastic
DG02938 Immune checkpoint inhibitor
D10390 Pidilizumab
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Other cell surface molecules
Immune checkpoints
PDCD1 (PD1, CD279)
D10390 Pidilizumab (USAN/INN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
